Paper39015802
Robust anti-tumor immunity through the integration of targeted lipid nanoparticle-based mRNA nanovaccines with PD-1/PD-L1 blockade.
Jin C and 5 others. Mater Today Bio, 2024. Cited by 20 papers, by iCite.
Cite this record
ConductScience Library. Robust anti-tumor immunity through the integration of targeted lipid nanoparticle-based mRNA nanovaccines with PD-1/PD-L1 blockade. Papers, record 39015802. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39015802
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Robust anti-tumor immunity through the integration of targeted lipid nanoparticle-based mRNA nanovaccines with PD-1/PD-L1 blockade.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References42
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 36209263 | Tumor microenvironment and immunotherapy of oral cancer. | Eur J Med Res | 2022 | https://conductscience.org/library/papers/36209263 | PubMed |
| 2 | 36638189 | Selective STING stimulation in dendritic cells primes antitumor T cell responses. | Sci Immunol | 2023 | https://conductscience.org/library/papers/36638189 | PubMed |
| 3 | 37877690 | A Self-Immolative DNA Nanogel Vaccine toward Cancer Immunotherapy. | Nano Lett | 2023 | https://conductscience.org/library/papers/37877690 | PubMed |
| 4 | 36604431 | Neoantigens: promising targets for cancer therapy. | Signal Transduct Target Ther | 2023 | https://conductscience.org/library/papers/36604431 | PubMed |
| 5 | 35994713 | Novel Cocktail Therapy Based on a Nanocarrier with an Efficient Transcytosis Property Reverses the Dynamically Deteriorating Tumor Microenvironment for Enhanced Immunotherapy. | Nano Lett | 2022 | https://conductscience.org/library/papers/35994713 | PubMed |
| 6 | 36322666 | Multiplexed high-throughput immune cell imaging reveals molecular health-associated phenotypes. | Sci Adv | 2022 | https://conductscience.org/library/papers/36322666 | PubMed |
| 7 | 33378609 | Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. | N Engl J Med | 2021 | https://conductscience.org/library/papers/33378609 | PubMed |
| 8 | 32357402 | Development of Polyelectrolyte Complexes for the Delivery of Peptide-Based Subunit Vaccines against Group A Streptococcus. | Nanomaterials (Basel) | 2020 | https://conductscience.org/library/papers/32357402 | PubMed |
| 9 | 21900389 | Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma. | Clin Cancer Res | 2011 | https://conductscience.org/library/papers/21900389 | PubMed |
| 10 | 30736848 | Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer. | J Immunother Cancer | 2019 | https://conductscience.org/library/papers/30736848 | PubMed |
| 11 | 35874717 | Immunotherapy: Reshape the Tumor Immune Microenvironment. | Front Immunol | 2022 | https://conductscience.org/library/papers/35874717 | PubMed |
| 12 | 35020204 | Cancer statistics, 2022. | CA Cancer J Clin | 2022 | https://conductscience.org/library/papers/35020204 | PubMed |
| 13 | 34594036 | Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors. | Nat Med | 2021 | https://conductscience.org/library/papers/34594036 | PubMed |
| 14 | 36113330 | A generally minimalist strategy of constructing biomineralized high-efficiency personalized nanovaccine combined with immune checkpoint blockade for cancer immunotherapy. | Biomaterials | 2022 | https://conductscience.org/library/papers/36113330 | PubMed |
| 15 | 37002376 | The role of macrophages in the tumor microenvironment and tumor metabolism. | Semin Immunopathol | 2023 | https://conductscience.org/library/papers/37002376 | PubMed |
| 16 | 37159807 | Cancer Cell Membrane-Coated Gambogic Acid Nanoparticles for Effective Anticancer Vaccination by Activating Dendritic Cells. | Int J Nanomedicine | 2023 | https://conductscience.org/library/papers/37159807 | PubMed |
| 17 | 25233993 | mRNA-based therapeutics--developing a new class of drugs. | Nat Rev Drug Discov | 2014 | https://conductscience.org/library/papers/25233993 | PubMed |
| 18 | 38516806 | A polyamino acid-based phosphatidyl polymer library for in vivo mRNA delivery with spleen targeting ability. | Mater Horiz | 2024 | https://conductscience.org/library/papers/38516806 | PubMed |
| 19 | 36591226 | mRNA vaccines for cancer immunotherapy. | Front Immunol | 2022 | https://conductscience.org/library/papers/36591226 | PubMed |
| 20 | 38348177 | Precision USPIO-PEG-SLex Nanotheranostic Agent Targeted Photothermal Therapy for Enhanced Anti-PD-L1 Immunotherapy to Treat Immunotherapy Resistance. | Int J Nanomedicine | 2024 | https://conductscience.org/library/papers/38348177 | PubMed |
Cited by13
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 20 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42941797 | Recent Advances in Lipid Nanoparticles for Cancer Vaccines: From Antigen Delivery to Personalized Immunotherapy. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42941797 | PubMed |
| 42455409 | Smart nanoparticle vaccines integrate nanotechnology artificial intelligence and immunoengineering for precision immunization. | Discov Nano | 2026 | https://conductscience.org/library/papers/42455409 | PubMed |
| 41677522 | Nanomaterial-Enabled Modulation of Tumor-Associated Macrophages and Dendritic Cells to Enhance Cancer Immunotherapy. | Nanomaterials (Basel) | 2026 | https://conductscience.org/library/papers/41677522 | PubMed |
| 41638631 | Biomimetic and personalized nanovaccines in cancer immunotherapy: Design innovations, translational challenges, and future directions. | J Adv Res | 2026 | https://conductscience.org/library/papers/41638631 | PubMed |
| 41584362 | Concerns and challenges in clinics-guided nanovaccines design and applications. | Acta Pharm Sin B | 2026 | https://conductscience.org/library/papers/41584362 | PubMed |
| 41479883 | Targeting persistently activated inflammatory microenvironment to promote chronic wound healing. | Front Immunol | 2025 | https://conductscience.org/library/papers/41479883 | PubMed |
| 41377933 | mRNA Cancer Vaccines: From Pandemic Paradigm to Personalized Oncology Therapeutics. | Cancer Innov | 2025 | https://conductscience.org/library/papers/41377933 | PubMed |
| 41181604 | Novel strategies for nanovaccine application in breast cancer treatment. | Front Pharmacol | 2025 | https://conductscience.org/library/papers/41181604 | PubMed |
| 41080724 | Lipid nanoparticle-mediated mRNA/siRNA dual-bioengineered dendritic cell vaccines combined of PD-1/PD-L1 blockade for boosting tumor immunotherapy. | Mater Today Bio | 2025 | https://conductscience.org/library/papers/41080724 | PubMed |
| 41032607 | Enhancing mRNA therapy through iterative delivery. | Sci Adv | 2025 | https://conductscience.org/library/papers/41032607 | PubMed |
| 41012179 | Messenger RNA and Plasmid DNA Vaccines for the Treatment of Cancer. | Vaccines (Basel) | 2025 | https://conductscience.org/library/papers/41012179 | PubMed |
| 40709686 | Developing Biomaterial-Based mRNA Delivery System for Lung Disease Treatment. | Adv Sci (Weinh) | 2025 | https://conductscience.org/library/papers/40709686 | PubMed |
| 40573881 | Synergistic Integration of HDAC Inhibitors and Individualized Neoantigen Therapy (INT): A Next-Generation Combinatorial Approach for Cancer Immunotherapy. | Vaccines (Basel) | 2025 | https://conductscience.org/library/papers/40573881 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CD274 | 29126 | PubTator's text mining | https://conductscience.org/library/genes/29126 | NCBI Gene |
| PDCD1 | 5133 | PubTator's text mining | https://conductscience.org/library/genes/5133 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39015802
GET https://conductscience.org/api/papers/v1/39015802/references?page=2